YLYitong Liu

Yitong Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yitong Liu has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety Assessment for Ingested N-acetylcysteine Exposure: A Systematic Review

    by Leslie Tompkins Steen, Andrew Shen, Michael F Santillo, Anneliese Striz, Laura Ewing, Kelly Harris, Yitong Liu, Sebnem Eren Cevik, Zheng Tu, Jeffrey J Yourick, et al.

    N-acetylcysteine (NAC), an amino acid precursor, is an approved drug in the United States and sold in products represented as dietary supplements. Currently, NAC is excluded from the statutory definition of a dietary supplement because of its approved drug status. The U.S. Food and Drug Administration (FDA) has the authority to remove this exclusion by regulation. As part of evaluating whether to pursue rulemaking, FDA has considered NAC’s safety profile. Adverse effects (AEs) from investigational uses of NAC include gastrointestinal symptoms, such as nausea and vomiting, plus rash with or without fever. However, similar AE reports on use of NAC as a dietary supplement were unavailable. To address this data gap, a systematic review (SR) was conducted to assess AEs associated with NAC, as it relates to an expectation of safety for NAC as a dietary supplement. The SR identified 41 high-quality studies from 149 studies reviewed. One study identified a statistically significant increase in nausea in patients with ulcerative colitis at a dose of 800 mg/day for 16 weeks. The remaining high-quality studies found no corresponding increase in AEs with high doses (up to 9000 mg/day) and long durations (up to 3 yrs). NAC doses in clinical studies were comparable to recommended servings of available NAC-containing products represented as supplements, indicating similar exposure levels and, therefore, a similar safety profile. Based on that similarity and the minimal level of concern for AEs associated with NAC, this review concludes a reasonable expectation of safety for NAC as a dietary supplement.

  • Open Access

    Translating in vitro mechanistic findings to in vivo toxicity outcomes: A case study of Usnic acid hepatotoxicity

    by Yitong Liu, Si Chen, Xiugong Gao, Kirsten Eckstrum, Lei Guo, Kayla Campasino, Kyra Headrick


  • Open Access

    Developing a Screening Strategy to Identify Hepatotoxicity and Drug Interaction Potential of Botanicals

    by Amy L. Roe, Julie Krzykwa, Angela I. Calderón, Cécile Bascoul, Bill J. Gurley, Igor Koturbash, Albert P. Li, Yitong Liu, Constance A. Mitchell, Hellen Oketch-Rabah, et al.

    Botanical supplements, herbal remedies, and plant-derived products are used globally. However, botanical dietary supplements are rarely subjected to robust safety testing unless there are adverse reports in post-market surveillance. Botanicals are complex and difficult to assess using current frameworks designed for single constituent substances (e.g. small molecules or discrete chemicals), making safety assessments costly and time-consuming. The liver is a primary organ of concern for potential botanical-induced hepatotoxicity and botanical-drug interactions as it plays a crucial role in xenobiotic metabolism. The NIH-funded Drug Induced Liver Injury Network noted that the number of botanical-induced liver injuries in 2017 nearly tripled from those observed in 2004-2005. New approach methodologies (NAMs) can aid in the rapid and cost-effective assessment of botanical supplements for potential hepatotoxicity. The Hepatotoxicity Working Group within the Botanical Safety Consortium is working to develop a screening strategy that can help reliably identify potential hepatotoxic botanicals and inform mechanisms of toxicity. This manuscript outlines the Hepatotoxicity Working Group's strategy and describes the assays selected and the rationale for the selection of botanicals used in case studies. The selected NAMs evaluated as a part of this effort are intended to be incorporated into a larger battery of assays to evaluate multiple endpoints related to botanical safety. This work will contribute to a botanical safety toolkit, providing researchers with tools to better understand hepatotoxicity associated with botanicals, prioritize and plan future testing as needed, and gain a deeper insight into the botanicals being tested.


  • Open Access

    Transcriptome and metabolome analyses reveal the regulatory role of MdPYL9 in drought resistance in apple

    by Mingxiao Liu, Yitong Liu, Wei Hu, Baoying Yin, Bowen Liang, Zhongyong Li, Xueying Zhang, Jizhong Xu, Shasha Zhou

    Background: The mechanisms by which the apple MdPYL9 gene mediates the response to drought stress remain unclear. Here, transcriptome and metabolome analyses of apple plants under drought were used to investigate the mechanisms by which MdPYL9 regulates the response to drought stress in apple. MdPYL9-overexpressed transgenic and non-transgenic apple histoculture seedlings were rooted, transplanted, and subjected to drought treatments to clarify the mechanisms underlying the responses of apples to drought stress through phenotypic observations, physiological and biochemical index measurements, and transcriptomic and metabolomic analyses. Results: Under drought stress treatment, transgenic plants were less affected by drought stress than non-transgenic plants. Decreases in the net photosynthetic rate, stomatal conductance, and transpiration rate of transgenic apple plants were less pronounced in transgenic plants than in non-transgenic plants, and increases in the intercellular CO2 concentration were less pronounced in transgenic plants than in non-transgenic plants. The relative electrical conductivity and content of malondialdehyde, superoxide anion, and hydrogen peroxide were significantly lower in transgenic plants than in non-transgenic plants, and the chlorophyll content and activities of antioxidant enzymes (superoxide dismutase, peroxidase, and catalase) were significantly higher in transgenic plants than in non-transgenic plants. The number of differentially expressed genes (DEGs) involved in the response to drought stress was lower in transgenic plants than in non-transgenic plants, and the most significant and highly annotated DEGs in the transgenic plants were involved in the flavonoid biosynthesis pathway, and the most significant and highly annotated DEGs in control plants were involved in the phytohormone signal transduction pathway. The number of differentially accumulated metabolites involved in the response to drought stress was lower in transgenic plants than in non-transgenic plants, and up-regulated metabolites were significantly enriched in apigenin-7-O-glucoside in transgenic plants and in abscisic acid in non-transgenic plants. In the flavonoid biosynthetic pathway, the expression of genes encoding chalcone synthase (CHS) and chalcone isomerase (CHI) was more significantly down-regulated in non-transgenic plants than in transgenic plants, and the expression of the gene encoding 4-coumarate-CoA ligase (4CL) was more significantly up-regulated in transgenic plants than in non-transgenic plants, which resulted in the significant up-regulation of apigenin-7-O-glucoside in transgenic plants. Conclusions: The above results indicated that the over-expression of MdPYL9 increased the drought resistance of plants under drought stress by attenuating the down-regulation of the expression of genes encoding CHS and CHI and enhancing the up-regulated expression of the gene encoding 4CL, which enhanced the content of apigenin-7-O-glucoside.


  • Open Access

    Prediction of physicochemical and pharmacokinetic properties of botanical constituents by computational models

    by Yitong Liu, Michael Lawless, Miao Li, Kiara Fairman, Michelle R. Embry, Constance A. Mitchell

    Botanicals contain complex mixtures of chemicals most of which lack pharmacokinetic data in humans. Since physicochemical and pharmacokinetic properties dictate the in vivo exposure of botanical constituents, these parameters greatly impact the pharmacological and toxicological effects of botanicals in consumer products. This study sought to use computational (i.e., in silico) models, including quantitative structure–activity relationships (QSAR) and physiologically based pharmacokinetic (PBPK) modeling, to predict properties of botanical constituents. One hundred and three major constituents (e.g., withanolides, mitragynine, and yohimbine) in 13 botanicals (e.g., ashwagandha, kratom, and yohimbe) were investigated. The predicted properties included biopharmaceutical classification system (BCS) classes based on aqueous solubility and permeability, oral absorption, liver microsomal clearance, oral bioavailability, and others. Over half of these constituents fell into BCS classes I and II at dose levels no greater than 100 mg per day, indicating high permeability and absorption (%Fa > 75%) in the gastrointestinal tract. However, some constituents such as glycosides in ashwagandha and Asian ginseng showed low bioavailability after oral administration due to poor absorption (BCS classes III and IV, %Fa < 40%). These in silico results fill data gaps for botanical constituents and could guide future safety studies. For example, the predicted human plasma concentrations may help select concentrations for in vitro toxicity testing. Additionally, the in silico data could be used in tiered or batteries of assays to assess the safety of botanical products. For example, highly absorbed botanical constituents indicate potential high exposure in the body, which could lead to toxic effects.


  • Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues

    by Yitong Liu, Robert L. Sprando

    There has been an increased public interest in developing consumer products containing nonintoxicating cannabinoids, such as cannabidiol (CBD) and cannabigerol (CBG). At the present time, there is limited information available on the pharmacokinetics of cannabinoids in humans. Since pharmacokinetic profiles are important in understanding the pharmacological and toxicological effects at the target sites, physiologically based pharmacokinetic (PBPK) modeling was used to predict the plasma and tissue concentrations of 17 cannabinoids in humans. PBPK models were established using measured (in vitro) and predicted (in silico) physicochemical and pharmacokinetic properties, such as water solubility and effective human jejunal permeability. Initially, PBPK models were established for CBD and the model performance was evaluated using reported clinical data after intravenous and oral administration. PBPK models were then developed for 16 additional cannabinoids including CBG, and the plasma and tissue concentrations were predicted after 30 mg oral administration. The pharmacokinetic profiles of the 16 cannabinoids were similar to CBD, and the plasma concentration and time profiles of CBD agreed well with clinical data in the literature. Although low exposure was predicted in the plasma (maximum plasma concentrations < 15 nM), the predicted tissue concentrations, especially the liver (maximum liver concentrations 70–183 nM), were higher after oral administration of 30 mg cannabinoids. These predicted plasma and tissue concentrations could be used to guide further in vitro and in vivo testing.


  • Study Liver Cytochrome P450 3A4 Inhibition and Hepatotoxicity Using DMSO-Differentiated HuH-7 Cells

    by Yitong Liu

    Metabolically competent, inexpensive, and robust in vitro cell models are needed for studying liver drug-metabolizing enzymes and hepatotoxicity. Human hepatoma HuH-7 cells develop into a differentiated in vitro model resembling primary human hepatocytes after a 2-week dimethyl sulfoxide (DMSO) treatment. DMSO-differentiated HuH-7 cells express elevated cytochrome P450 3A4 (CYP3A4) enzyme gene expression and activity compared to untreated HuH-7 cells. This cell model could be used to study CYP3A4 inhibition by reversible and time-dependent inhibitors, such as drugs, food ingredients, and environmental chemicals. The DMSO-differentiated HuH-7 model is also a suitable tool for investigating hepatotoxicity. This chapter describes a detailed methodology for developing DMSO-differentiated HuH-7 cells, which are subsequently used for CYP3A4 inhibition and hepatotoxicity studies.

  • Use In Silico and In Vitro Methods to Screen Hepatotoxic Chemicals and CYP450 Enzyme Inhibitors

    by Yitong Liu

    In silico and in vitro methods have emerged as valuable tools to rapidly screen and prioritize large numbers of chemicals including new drug entities, food ingredients, and environmental compounds for further in vivo analysis. These methods have been frequently used to conduct screening for a wide range of endpoints including physicochemical properties (e.g., logD), human biokinetic parameters (e.g., metabolism), and human organ toxicities (e.g., hepatotoxicity). This chapter describes a tiered approach of incorporating multiple in silico (quantitative structure–activity relationship, QSAR) and in vitro (e.g., human liver cell models, human liver microsomes) methods into the screening of hepatotoxic chemicals and cytochromes P450 enzyme (CYP) inhibitors. Chemicals are prioritized for further studies (e.g., in vivo animal study) based on the in silico and in vitro results, as well as a literature search for their in vivo exposures (e.g., plasma concentration).